ZENTALIS PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.28 USD | -3.22% |
|
-5.60% | -25.41% |
Financials (USD)
| Sales 2024 * | 32.81M | Sales 2025 * | 2.68M | Capitalization | 827M |
|---|---|---|---|---|---|
| Net income 2024 * | -193M | Net income 2025 * | -299M | EV / Sales 2024 * | 9.11 x |
| Net cash position 2024 * | 528M | Net cash position 2025 * | 356M | EV / Sales 2025 * | 176 x |
| P/E ratio 2024 * |
-4.31
x | P/E ratio 2025 * |
-3.15
x | Employees | 124 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.2% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zentalis Pharmaceuticals, Inc.
More recommendations
More press releases
| 1 day | +1.84% | ||
| 1 week | +0.26% | ||
| Current month | -1.94% | ||
| 1 month | -0.51% | ||
| 3 months | -18.30% | ||
| Current year | -23.10% |
1 week
11.10
13.00
1 month
10.9813.24
Current year
10.3918.07
1 year
9.5630.53
3 years
9.5687.19
5 years
9.5687.19
10 years
9.5687.19
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 20-06-30 | |
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Mark Lackner
CTO | Chief Tech/Sci/R&D Officer | 56 | 22-10-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Diana Hausman
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-05-07 |
Karan Takhar
BRD | Director/Board Member | 32 | 17-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.11% | 0 M€ | 0.00% | - | |
| 0.09% | 0 M€ | 0.00% | - | |
| 0.07% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 11.3 | -3.00% | 184 045 |
| 24-06-05 | 11.65 | +1.84% | 503,994 |
| 24-06-04 | 11.44 | +0.35% | 412,625 |
| 24-06-03 | 11.4 | -4.04% | 842,928 |
| 24-05-31 | 11.88 | -0.75% | 838,191 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotes
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Companyâs lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Calendar
2024-06-21
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
11.65
USD
Average target price
33.4
USD
Spread / Average Target
+186.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.10% | 827M | |
| +18.72% | 125B | |
| +14.53% | 109B | |
| -2.88% | 24.74B | |
| +3.70% | 22.67B | |
| -10.09% | 18.14B | |
| -41.04% | 16.67B | |
| -11.83% | 16.64B | |
| +1.46% | 13.45B | |
| +24.22% | 11.32B |
- Stock Market
- Equities
- ZNTL Stock
